KBC Group
LEGN icon

KBC Group’s Legend Biotech LEGN Stock Holding History

KBC Group’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$242K Buy
8,390
+778
+10% +$21K ﹤0.01% 974
2026
Q1 		$138K Sell
7,612
-11,902
-61% -$227K ﹤0.01% 1131
2025
Q4 		$424K Hold
19,514
– – ﹤0.01% 739
2025
Q3 		$636K Buy
19,514
+2,431
+14% +$89.8K ﹤0.01% 693
2025
Q2 		$606K Sell
17,083
-9,965
-37% -$323K ﹤0.01% 690
2025
Q1 		$918K Buy
27,048
+13,904
+106% +$499K ﹤0.01% 674
2024
Q4 		$428K Hold
13,144
– – ﹤0.01% 840
2024
Q3 		$641K Hold
13,144
– – ﹤0.01% 703
2024
Q2 		$582K Hold
13,144
– – ﹤0.01% 708
2024
Q1 		$737K Sell
13,144
-2,787
-17% -$168K ﹤0.01% 697
2023
Q4 		$959K Buy
15,931
+522
+3% +$33.1K ﹤0.01% 695
2023
Q3 		$1.03M Sell
15,409
-942
-6% -$65.4K ﹤0.01% 677
2023
Q2 		$1.13M Sell
16,351
-1,000
-6% -$65.3K ﹤0.01% 684
2023
Q1 		$837K Sell
17,351
-1,200
-6% -$58.7K ﹤0.01% 732
2022
Q4 		$926K Sell
18,551
-2,108
-10% -$102K ﹤0.01% 698
2022
Q3 		$843K Sell
20,659
-1,309
-6% -$61.4K ﹤0.01% 691
2022
Q2 		$1.21M Sell
21,968
-10,897
-33% -$460K 0.01% 635
2022
Q1 		$1.19M Buy
32,865
+7,035
+27% +$278K ﹤0.01% 673
2021
Q4 		$1.2M Buy
25,830
+5,702
+28% +$289K ﹤0.01% 692
2021
Q3 		$1.02M Sell
20,128
-7,126
-26% -$297K ﹤0.01% 757
2021
Q2 		$1.12M Hold
27,254
– – ﹤0.01% 755
2021
Q1 		$791K Buy
27,254
+5,385
+25% +$147K ﹤0.01% 789
2020
Q4 		$616K Sell
21,869
-45,297
-67% -$1.3M ﹤0.01% 825
2020
Q3 		$2.07M Buy
+67,166
New +$2.26M 0.01% 584

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

KBC Group's LEGN Position: Q2 2026 in Review

KBC Group increased its Legend Biotech (LEGN) stake by 10% in Q2 2026, buying an estimated $21K and bringing the position to 8,390 shares worth $242K. The position accounts for ﹤0.01% of the portfolio, ranked #974.

KBC Group first reported a position in LEGN in Q3 2020 and has held it in 24 quarters since. The position peaked at $2.07M in Q3 2020. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • KBC Group held 8,390 shares of Legend Biotech worth $242K as of Q2 2026.
  • KBC Group bought 778 Legend Biotech shares in Q2 2026, an estimated $21K.
  • Legend Biotech made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #974 holding.
  • KBC Group first reported a position in Legend Biotech in Q3 2020 and has held it in 24 quarters since.
  • KBC Group's Legend Biotech position peaked at $2.07M in Q3 2020.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.